| Literature DB >> 32509463 |
Juwairiah Remali1, Wan Mohd Aizat2, Chyan Leong Ng2, Yi Chieh Lim3, Zeti-Azura Mohamed-Hussein2,4, Shazrul Fazry1,5.
Abstract
BACKGROUND: DNA double strand break repair is important to preserve the fidelity of our genetic makeup after DNA damage. Rad50 is one of the components in MRN complex important for DNA repair mechanism. Rad50 mutations can lead to microcephaly, mental retardation and growth retardation in human. However, Rad50 mutations in human and other organisms have never been gathered and heuristically compared for their deleterious effects. It is important to assess the conserved region in Rad50 and its homolog to identify vital mutations that can affect functions of the protein.Entities:
Keywords: DNA damage; Rad50; Rad50 in silico model; Rad50 mutation; Rad50 related diseases
Year: 2020 PMID: 32509463 PMCID: PMC7247530 DOI: 10.7717/peerj.9197
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
Figure 1Domain analysis and multiple sequence alignment.
Domain analysis using InterPro shows that Rad50 contains P-loop containing nucleoside triphosphate hydrolase domain belongs to the ATP Binding Cassette (ABC) protein superfamily (pink box) as well as a special domain called zinc hook, which so far does not overlap with any homologous superfamilies (blue box) (a). ABC protein consists of six conserved motifs; that is, Walker A (WA), Q-loop (QL), signature motif (SM), Walker B (WB), D-loop (DL), and H-loop (HL) which make up the nucleotide binding domain. Zinc hook domain contains a conserved CxxC motif located at the residue number 681–684 (A). All deleterious residues identified from the literature were highlighted based on human equivalent mutation (Table S1) and those occurring only in the conserved regions are shown in (B). Multiple sequence alignment (MSA) analysis of Rad50 sequences dataset (human, D. rerio (zebrafish), M. musculus (mouse), R. norvegicus (rat), P. troglodytes (chimpanzee), O. cuniculus (rabbit), D. melanogaster (fruit fly), S. cerevisiae (yeast) and S. pombe (yeast)) showed conserved residues in specific motifs (B). An “*” (asterisk) indicates position which has a single, fully conserved residue. A “:” (colon) indicates conservation between groups of strongly similar properties—scoring > 0.5 in the Gonnet PAM250 matrix. A “.” (period) indicates conservation between groups of weakly similar properties—scoring ≤ 0.5 in the Gonnet PAM250 matrix.
Summary of the most damaging effects of Rad50 mutations obtained from previous in vitro and in vivo experiments.
| Motif/domain | Mutations | Organism | Effects | References |
|---|---|---|---|---|
| Walker A | K40A/R/E | • HR and NHEJ defects and lower ATPase activity | ||
| Walker A D-loop | N38A, D512N/A | T4 bacteriophage | • Naturally occurring mutation of CFTR protein | |
| • Reduce in ATP activity | ||||
| ATP binding domain and Walker A | G39D, K40E, K81I, R20M | • Total defect in formation of viable spore | ||
| ATP binding domain | K6E, K22M, R83I | • Embryonic lethality, growth defect, cancer predisposition, hematopoietic and spermatogenic depletion | ||
| Walker A | K39R, K42M | • Prevented ATP binding and hydrolysis | ||
| ATPase binding domain, Walker B and Signature motif | K115E, K175E, K182E, R94E, K95E, R765E | In vitro: | ||
| • K175E, K182E, K115E Reduced DNA binding | ||||
| • R94E and K95E: Important for DNA binding | ||||
| • R765E: Diminished DNA binding | ||||
| • E798Q: Low affinity to DNA | ||||
| • S768R: Reduced DNA binding | ||||
| E798Q, S768R, K103E, K104E, R131E, R1202E, S1205R, E1235Q | In vivo: | |||
| • S1205R and E1235Q double mutation: Unable to rescue the impaired DNA damage response | ||||
| • K103E, K104E and R131E: Strongly affected DNA binding and moderate reduction in telomere length | ||||
| • K103E and R131R (double mutation) and R1201E: Significantly reduced telomere length | ||||
| • S1205R: Significantly reduced telomere length | ||||
| Zinc hook | S679R, P682E, V683R | • Lethality in mice. Hydrocephalus, defects in primitive hematopoietic and gametogenic cells | ||
| C684N, C685A, P686A, V6871, C688R, Q689S | • Defective to be recruited to chromosomal double strand break | |||
| • Phenotype as severe as Rad50 null mutant | ||||
| • Defective in ATM activation, HR, sensitive to irradiation and ATR activation | ||||
| C288S, C291S | T4 bacteriophage | • Double mutation is lethal | ||
| S635G | • Chromosomal instability | |||
| • Defective ATM-dependent signaling | ||||
| S685R, Y688E, L689R | • S685R and Y688E double mutation: Sporulation efficiency and viability were severely impaired followed by L689R | |||
| • Rad50-Mre11 interaction was strongly impaired, partial suppression of telomere and meiotic defects | ||||
| Rad50 Signature motif | R805E, L802W | • L802W: Decrease dimerization in ATP, hydrolysis and cleavage site | ||
| • R805E: Poorly grown in camptothecin; inability to repair endogenous DNA damage by HR and showed defect in resection in HO endonuclease induced | ||||
| K1187A, K1187E, R1195A, R1195E | • K1187A: Sensitive in higher dose of clastogens | |||
| • K1187E, R1195A and R1195E: Significantly sensitive to clastogen agents and were deleterious as Rad50 null mutation | ||||
| S471A/R/M, E474Q, K475M | T4 bacteriophage | • S471A/R.M, E474Q and K475M: Residues involved in the allosteric transmission between DNA and ATP binding sites | ||
| S1205R | • S1202R: Reduced adenylate kinase | |||
| S793R | • S793R: Deficient in ATP-dependent dimer formation and ATP binding | |||
| S1202R | • S1202R and S1205R: Low level of adenylate kinase | |||
| • S1205R: Telomere shortening, not support spore viability | ||||
| Signature motif and Q loop | S793R, Q140H | • S793R: Analogs to the mutation in CFTR (S549R) gene that results cystic fibrosis | ||
| • S793R: Prevented ATP binding | ||||
| S1205R | • S1205R | |||
| • S783R and Q140H: Halted ATP-dependent activities | ||||
| ATPase domain | R1093 (stop) c.3939A/T | • Nijmegen breakage syndrome like disorder (NBSLD) |
Note:
HR, homologous recombination; NHEJ, non-homologous end joining repair; CFTR, cystic fibrosis transmembrane conductance regulator; ATP, adenosine tri-phosphate; ATM, ataxia-telangiectasia mutated; ATR, ATM-and Rad3-Related. Refer to Table S2 for the description of all mutations.
Figure 23D structure of Rad50.
A 3D structure of Rad50 human modeled using fold recognition technique Phyre2 using structure from Chaetomium thermophilum as a template (PDB ID: 5DAC). N-terminal of 276 residues (2-278) and C-terminal of 155 residues (1153-1306) are colored as blue and green, respectively (A). All six motifs identified are marked and represented by ball and stick representation with different colors (orange for Q-loop, blue for Walker B, purple for signature motif, yellow for D-loop, gray for Walker A and green from H-loop) (A). All mutated residues identified were marked and labeled in the 3D structure (B). Zinc hook structure of 181 residues (residue 585-766) that has been determined (PDB ID: 5GOX) and its deleterious residues also marked in the structure (C and D). All figures were generated using UCSF Chimera (Pettersen et al., 2004).
In silico analysis of 42 deleterious mutations in Rad50.
| Amino acid impact (PredictSNP) (neutral/deleterious) | Molecular mechanisms (MutPred2) | Structural phenotyping (SNPeffect) | Protein stability (imutant/MuPro) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Motif | Mutation (source) | PS | MP | Ph-S | PP-1 | PP-2 | SF | SP | Affected molecular mechanisms | Pr | Affected functional sites | AG | AM | IM | MPr | |
| Walker A | N38A ( | D | D | D | D | D | D | D | Loss of catalytic site at N38 | 0.53 | 8.80E−05 | • ATP/GTP-binding site motif A (P-loop) | No | No | ↓ | ↓ |
| Loss of relative solvent accessibility | 0.34 | 3.40E−03 | ||||||||||||||
| Altered ordered interface | 0.33 | 9.90E−03 | ||||||||||||||
| Loss of allosteric site at N38 | 0.31 | 3.00E−03 | ||||||||||||||
| Altered DNA binding | 0.25 | 6.70E−03 | ||||||||||||||
| Altered metal binding | 0.23 | 0.02 | ||||||||||||||
| Gain of methylation at K42 | 0.17 | 8.40E−03 | ||||||||||||||
| G41D ( | D | D | D | D | D | D | D | Altered metal binding | 0.40 | 1.70E−04 | • FHA phosphopeptide ligands | No | No | ↓ | ↓ | |
| Gain of allosteric site at G41 | 0.33 | 6.40E−04 | • CK2 Phosphorylation site | |||||||||||||
| Altered ordered interface | 0.30 | 0.02 | • N-myristoylation site | |||||||||||||
| Gain of relative solvent accessibility | 0.29 | 0.01 | • ATP/GTP-binding site motif A (P-loop) | |||||||||||||
| Gain of helix | 0.29 | 0.01 | ||||||||||||||
| Loss of strand | 0.28 | 9.70E−03 | ||||||||||||||
| Altered DNA binding | 0.28 | 4.30E−03 | ||||||||||||||
| Loss of catalytic site at N38 | 0.27 | 3.70E−03 | ||||||||||||||
| Loss of methylation at K42 | 0.17 | 0.01 | ||||||||||||||
| K42R ( | D | D | D | D | D | D | D | Loss of relative solvent accessibility | 0.30 | 9.60E−03 | • FHA phosphopeptide ligands | No | No | ↓ | ↓ | |
| Altered DNA binding | 0.28 | 3.20E−03 | • PKA phosphorylation site | |||||||||||||
| Loss of allosteric site at T44 | 0.28 | 7.30E−03 | • CK2 phosphorylation site | |||||||||||||
| Loss of catalytic site at N38 | 0.27 | 3.40E−03 | • N-myristoylation site | |||||||||||||
| Altered metal binding | 0.25 | 0.01 | • ATP/GTP-binding site motif A (P-loop) | |||||||||||||
| Loss of methylation at K42 | 0.20 | 6.90E−03 | ||||||||||||||
| K42M ( | D | D | D | D | D | D | D | Altered DNA binding | 0.37 | 7.10E−04 | • FHA phosphopeptide ligands | No | No | ↑ | ↑ | |
| Loss of allosteric site at K42 | 0.36 | 1.10E−03 | • CK2 phosphorylation site | |||||||||||||
| Loss of relative solvent accessibility | 0.34 | 3.10E−03 | • N-myristoylation site | |||||||||||||
| Altered ordered interface | 0.32 | 0.01 | • ATP/GTP-binding site motif A (P-loop) | |||||||||||||
| Gain of catalytic site at T43 | 0.29 | 1.60E−03 | ||||||||||||||
| Altered metal binding | 0.28 | 5.80E−03 | ||||||||||||||
| Loss of methylation at K42 | 0.20 | 6.80E−03 | ||||||||||||||
| K42E ( | D | D | D | D | D | D | D | Altered metal binding | 0.44 | 4.50E−04 | • FHA phosphopeptide ligands | No | No | ↓ | ↓ | |
| Gain of catalytic site at T43 | 0.33 | 6.40E−04 | • CK2 phosphorylation site | |||||||||||||
| Altered DNA binding | 0.33 | 1.30E−03 | • Polo-like kinase phosphorylation sit | |||||||||||||
| Loss of allosteric site at K42 | 0.30 | 4.30E−03 | • N-myristoylation site | |||||||||||||
| Altered ordered interface | 0.29 | 0.02 | • ATP/GTP-binding site motif A (P-loop) | |||||||||||||
| Loss of relative solvent accessibility | 0.29 | 0.01 | ||||||||||||||
| Gain of strand | 0.27 | 0.03 | ||||||||||||||
| Loss of methylation at K42 | 0.20 | 6.80E−03 | ||||||||||||||
| K42A ( | D | D | D | D | D | D | D | Loss of allosteric site at K42 | 0.53 | 5.40E−05 | • FHA phosphopeptide ligands | No | No | ↓ | ↓ | |
| Loss of relative solvent accessibility | 0.37 | 1.60E−03 | • CK2 phosphorylation site | |||||||||||||
| Altered DNA binding | 0.37 | 6.00E−04 | • N-myristoylation site | |||||||||||||
| Altered ordered interface | 0.36 | 4.20E−03 | • ATP/GTP-binding site motif A (P-loop) | |||||||||||||
| Gain of catalytic site at T43 | 0.32 | 8.70E−04 | ||||||||||||||
| Altered metal binding | 0.31 | 0.01 | ||||||||||||||
| Loss of methylation at K42 | 0.20 | 6.80E−03 | ||||||||||||||
| Q-loop | Q159H ( | D | D | D | D | D | D | D | No effect | – | – | None | No | No | ↓ | ↓ |
| Zinc hook | S635G ( | N | N | N | D | N | N | N | No effect | – | – | None | No | No | ↓ | ↓ |
| S679R ( | N | N | N | N | N | D | N | No effect | – | – | None | No | No | ↓ | ↓ | |
| C680N ( | N | N | N | D | N | D | D | Loss of N-linked glycosylation at N677 | 0.02 | 0.04 | • N-glycosylation site | No | No | ↓ | ↓ | |
| C681A ( | D | D | D | D | D | D | D | Gain of helix | 0.30 | 8.00E−03 | • N-glycosylation site | No | No | ↓ | ↓ | |
| Gain of N-linked glycosylation at N677 | 0.02 | 0.03 | ||||||||||||||
| C681S ( | D | D | D | D | D | D | N | Gain of N-linked glycosylation at N677 | 0.02 | 0.04 | • N-glycosylation site | No | No | ↑ | ↓ | |
| • Proline-directed phosphorylation | ||||||||||||||||
| • MAPK phosphorylation site | ||||||||||||||||
| P682E ( | D | D | N | D | D | D | D | Gain of helix | 0.32 | 3.10E−03 | • CK2 phosphorylation site | No | No | ↓ | ↓ | |
| Altered coiled coil | 0.14 | 0.03 | ||||||||||||||
| Loss of N-linked glycosylation at N677 | 0.02 | 0.04 | ||||||||||||||
| P682A ( | N | N | N | N | D | D | N | No effect | – | – | None | No | No | ↓ | ↓ | |
| V683I ( | N | N | N | N | N | D | N | No effect | – | – | None | No | No | ↑ | ↑ | |
| V683R ( | N | N | N | N | N | D | D | Gain of helix | 0.29 | 0.01 | None | No | No | ↓ | ↓ | |
| C684R ( | D | D | D | D | D | D | D | Gain of helix | 0.30 | 9.50E−03 | • Diarginine retention/retrieving signal | No | No | ↓ | ↓ | |
| C684S ( | D | D | D | D | D | D | D | No effect | – | – | • PIKK phosphorylation site | No | No | ↓ | ↓ | |
| • PKC phosphorylation site | ||||||||||||||||
| Q685S ( | N | N | N | N | N | D | N | Altered coiled coil | 0.53 | 6.50E−03 | • BRCT phosphopeptide ligands | No | No | ↓ | ↓ | |
| • USP7 binding motif | ||||||||||||||||
| Signature motif | R1198E ( | D | D | D | D | D | D | D | Gain of catalytic site at R1200 | 0.25 | 4.80E−03 | • Diarginine retention/retrieving signal | No | No | ↓ | ↓ |
| Gain of allosteric site at R1200 | 0.21 | 0.03 | ||||||||||||||
| Altered metal binding | 0.14 | 0.03 | ||||||||||||||
| Altered transmembrane protein | 0.10 | 0.04 | ||||||||||||||
| G1199E ( | D | D | D | D | D | D | D | Loss of allosteric site at R1200 | 0.23 | 0.03 | • Diarginine retention/retrieving signal | No | No | ↓ | ↓ | |
| Loss of catalytic site at R1200 | 0.20 | 0.01 | • PKA phosphorylation site | |||||||||||||
| Altered transmembrane protein | 0.11 | 0.04 | ||||||||||||||
| S1202A ( | D | D | D | D | D | D | D | Loss of allosteric site at R1200 | 0.23 | 0.03 | • PKA phosphorylation site | No | No | ↓ | ↓ | |
| Loss of catalytic site at R1200 | 0.20 | 0.01 | • Glycosaminoglycan attachment site | |||||||||||||
| S1202R ( | D | D | D | D | D | D | D | Gain of ADP-ribosylation at S1202 | 0.25 | 8.40E−03 | • PKA phosphorylation site | No | No | ↑ | ↓ | |
| Loss of allosteric site at R1200 | 0.23 | 0.03 | • Glycosaminoglycan attachment site | |||||||||||||
| Loss of catalytic site at R1200 | 0.21 | 1.00E−02 | ||||||||||||||
| S1202M ( | D | D | D | D | D | D | D | Loss of allosteric site at R1200 | 0.23 | 0.02 | • PKA phosphorylation site | No | No | ↑ | ↑ | |
| Gain of catalytic site at R1200 | 0.21 | 9.70E−03 | • Glycosaminoglycan attachment site | |||||||||||||
| Q1205E ( | D | D | D | N | D | D | D | Gain of allosteric site at R1200 | 0.23 | 0.02 | • PKA phosphorylation site | ↑ | ↓ | ↓ | ↓ | |
| Loss of catalytic site at R1200 | 0.20 | 0.01 | • CK2 phosphorylation site | |||||||||||||
| K1206M ( | D | D | D | D | D | D | D | Gain of catalytic site at S1202 | 0.09 | 0.04 | None | ↑ | ↓ | ↑ | ↑ | |
| K1206A ( | D | D | D | D | D | D | D | Loss of catalytic site at K1206 | 0.09 | 0.05 | None | ↑ | ↓ | ↓ | ↑ | |
| K1206E ( | D | D | D | D | D | D | D | Gain of catalytic site at K1206 | 0.11 | 0.03 | • TRAF2 binding site | ↑ | ↓ | ↓ | ↑ | |
| • NES nuclear export signal | ||||||||||||||||
| L1211W ( | D | D | D | D | D | D | D | Loss of catalytic site at K1206 | 0.08 | 0.05 | • SUMO interaction site | ↑ | ↑ | ↓ | ↓ | |
| R1214A ( | D | D | D | D | D | D | D | Loss of allosteric site at R1214 | 0.22 | 0.03 | • ATP-binding cassette, ABC transporter-type, signature and profile | ↑ | ↓ | ↓ | ↓ | |
| R1214E ( | D | D | D | D | D | D | D | Loss of allosteric site at R1214 | 0.20 | 0.04 | • SUMO interaction site | ↑ | No | ↓ | ↓ | |
| • ATP-binding cassette, ABC transporter-type, signature and profile | ||||||||||||||||
| Walker B | E1232Q ( | D | D | D | D | D | D | D | Altered metal binding | 0.48 | 4.30E−03 | • FHA phosphopeptide ligands | No | No | ↓ | ↓ |
| Loss of catalytic site at E1232 | 0.34 | 9.80E−04 | • SUMO interaction site | |||||||||||||
| Loss of allosteric site at P1233 | 0.24 | 0.02 | ||||||||||||||
| Altered transmembrane protein | 0.12 | 0.03 | ||||||||||||||
| D-loop | D1238N ( | D | D | D | D | D | D | D | Altered ordered interface | 0.30 | 4.30E−03 | • FHA phosphopeptide ligands | No | No | ↓ | ↓ |
| Altered metal binding | 0.31 | 2.80E−03 | • Casein kinase II phosphorylation site | |||||||||||||
| Gain of relative solvent accessibility | 0.27 | 0.02 | ||||||||||||||
| Gain of allosteric site at P1233 | 0.25 | 0.01 | ||||||||||||||
| Loss of catalytic site at T1234 | 0.17 | 0.02 | ||||||||||||||
| Altered transmembrane protein | 0.12 | 0.03 | ||||||||||||||
| Altered coiled coil | 0.08 | 0.05 | ||||||||||||||
| D1238A ( | D | D | D | D | D | D | D | Altered metal binding | 0.41 | 3.40E−04 | • FHA phosphopeptide ligands | No | No | ↓ | ↓ | |
| Altered ordered interface | 0.40 | 1.40E−03 | • Casein kinase II phosphorylation site | |||||||||||||
| Loss of allosteric site at P1233 | 0.26 | 0.01 | ||||||||||||||
| Loss of catalytic site at T1234 | 0.18 | 0.02 | ||||||||||||||
| Altered transmembrane protein | 0.12 | 0.02 | ||||||||||||||
| ATPase domain/coiled-coil | K6E ( | D | D | D | D | D | N | D | Loss of strand | 0.27 | 0.03 | None | No | No | ↓ | ↓ |
| Altered DNA binding | 0.16 | 0.04 | ||||||||||||||
| Gain of N-terminal acetylation at M1 | 0.03 | 4.10E−03 | ||||||||||||||
| K22M ( | N | N | N | N | N | D | N | No effect | – | – | None | ↑ | No | ↓ | ↑ | |
| R83I ( | N | D | N | N | N | D | N | Altered ordered interface | 0.29 | 0.03 | • PP1-docking motif RVXF | ↑ | ↑ | ↓ | ↑ | |
| Altered DNA binding | 0.22 | 0.02 | ||||||||||||||
| Altered coiled coil | 0.10 | 0.04 | ||||||||||||||
| K132E ( | D | D | N | D | D | D | D | Loss of helix | 0.28 | 0.02 | • CK1 phosphorylation site | No | No | ↓ | ↓ | |
| Altered transmembrane protein | 0.27 | 7.30E−04 | • Protein kinase C phosphorylation site | |||||||||||||
| Gain of strand | 0.27 | 0.01 | ||||||||||||||
| T191E ( | N | D | N | N | N | N | N | Altered coiled coil | 0.28 | 0.01 | • TRAF2 binding site | No | No | ↓ | ↓ | |
| Loss of acetylation at K187 | 0.28 | 6.20E−03 | • NEK2 phosphorylation site | |||||||||||||
| • PKC phosphorylation site | ||||||||||||||||
| C221E ( | N | N | N | N | N | N | N | No effect | – | – | None | No | No | ↓ | ↓ | |
| K105E ( | D | N | D | D | D | D | D | No effect | – | – | None | No | No | ↓ | ↓ | |
| S106E ( | N | N | N | N | N | N | N | No effect | – | – | None | No | No | ↑ | ↓ | |
Note:
Different tools were used to analyze all mutations as abbreviated in the table. PS, PredictSNP; MP, MAPP; PhS, PhD-SNP; PP1, Poly-Phen1; PP2, Poly-Phen2; SF, SIFT; SN, SNAP; IM, I-Mutant; MPr, MuPro; Pr, probability; AG, protein aggregation; AM, Amyloid aggregation. Please refer to “Materials and Methods” for detailed descriptions of these tools. Note that all mutations listed above are based on the equivalent mutations in human.